DCT

2:26-cv-11002

Takeda Pharma USA Inc v. Polpharma Biologics SA

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 3:26-cv-11002, D.N.J., 08/26/2026
  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey because the defendant, Polpharma, is a foreign entity and is therefore subject to suit in any U.S. judicial district. The complaint also alleges Polpharma transacts business in New Jersey and intends to commit acts of patent infringement in the district.
  • Core Dispute: Plaintiff alleges that Defendant's abbreviated Biologics License Application (aBLA) for a proposed biosimilar version of ENTYVIO® (vedolizumab) constitutes an act of infringement and that the future commercialization of the product will infringe six U.S. patents covering methods of treating inflammatory bowel disease.
  • Technical Context: The technology involves a humanized monoclonal antibody, vedolizumab, which selectively targets the α4β7 integrin pathway to treat inflammatory bowel diseases like ulcerative colitis and Crohn's disease, a multi-billion dollar market.
  • Key Procedural History: This action was filed under the Biologics Price Competition and Innovation Act (BPCIA) following Defendant's submission of an aBLA to the U.S. Food and Drug Administration (FDA) to market a biosimilar version of Plaintiff's ENTYVIO® product. The complaint states Defendant declined to participate in the pre-litigation information exchanges ("patent dance") outlined in the BPCIA. On June 18, 2026, Defendant provided Plaintiff with a Notice of Commercial Marketing.

Case Timeline

Date Event
2011-05-02 Earliest Priority Date for all Asserted Patents
2014-05-XX FDA first approves ENTYVIO® (intravenous)
2017-05-30 U.S. Patent No. 9,663,579 issues
2018-06-26 U.S. Patent No. 10,004,808 issues
2021-XX-XX Polpharma's efforts to copy ENTYVIO® reportedly begin
2023-07-24 Polpharma initiates Phase III clinical trial for PB016 biosimilar
2024-02-XX Polpharma announces pharmacokinetic/pharmacodynamic comparability of PB016 to ENTYVIO®
2024-04-XX FDA approves ENTYVIO® for subcutaneous delivery
2024-08-06 U.S. Patent No. 12,053,526 issues
2024-12-24 U.S. Patent No. 12,171,832 issues
2025-XX-XX Polpharma announces partnership with Fresenius Kabi to commercialize PB016
2026-02-10 U.S. Patent No. 12,544,445 issues
2026-05-12 U.S. Patent No. 12,622,969 issues
2026-06-18 Polpharma provides Takeda with a Notice of Commercial Marketing
2026-08-26 Complaint Filing Date
2026-12-15 Earliest potential launch date for Polpharma's aBLA Product

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,663,579 - "Formulation for anti-a4β7 Antibody"

  • Patent Identification: U.S. Patent No. 9,663,579, titled "Formulation for anti-a4β7 Antibody", issued May 30, 2017 Compl. ¶47

The Invention Explained

  • Problem Addressed: The patent addresses the challenge of treating patients with Crohn's disease (CD) who have had an inadequate response to, lost response to, or were intolerant to treatment with a TNFα antagonist Compl. ¶54, claim 1 This patient population represents a significant unmet medical need Compl. ¶5
  • The Patented Solution: The invention is a specific method of treatment comprising a three-dose intravenous induction regimen of 300 mg of vedolizumab (an antibody with specificity for human α4β7 integrin) administered at week 0, week 2, and week 6 Compl. ¶54, claim 1 The '808 patent, which is in the same family, explains that specific dosing regimens are needed to provide therapeutically effective blood levels of the antibody in a stable and convenient form '808 Patent, col. 2:36-49
  • Technical Importance: This specific induction-phase dosing regimen provided a new therapeutic option for a difficult-to-treat CD patient population that had exhausted other biologic therapies Compl. ¶5

Key Claims at a Glance

  • The complaint asserts infringement of at least claim 1 Compl. ¶56
  • The essential elements of independent claim 1 are:
    • A method for achieving clinical response of Crohn's disease in a human patient.
    • The patient is characterized as having had a lack of an adequate response with, lost response to, or was intolerant to a TNFα antagonist.
    • The method comprises intravenously administering a first dose of 300 mg of an α4β7-specific antibody, a second 300 mg dose two weeks later, and a third 300 mg dose six weeks after the first dose.
    • The antibody is defined by specific heavy and light chain variable region sequences (SEQ ID NO:2 and SEQ ID NO:4, respectively).

U.S. Patent No. 10,004,808 - "Methods of Treating Ulcerative Colitis"

  • Patent Identification: U.S. Patent No. 10,004,808, titled "Methods of Treating Ulcerative Colitis", issued June 26, 2018 Compl. ¶48

The Invention Explained

  • Problem Addressed: The patent's background describes the general problem of formulating protein therapeutics, which are prone to chemical and physical instability that can compromise their efficacy '808 Patent, col. 1:24-58 It specifically highlights the need for suitable dosages and dosing schedules for anti-α4β7 antibodies to treat inflammatory bowel diseases like ulcerative colitis (UC) '808 Patent, col. 2:36-49
  • The Patented Solution: The patent claims a method for inducing clinical remission of UC in patients who have previously failed TNFα antagonist therapy '808 Patent, claim 1 The method consists of a specific intravenous dosing regimen: an induction phase with 300 mg doses at weeks 0, 2, and 6, followed by a maintenance phase of 300 mg every eight weeks thereafter '808 Patent, claim 1
  • Technical Importance: This dosing regimen established a method for not only inducing but also maintaining clinical remission in a UC patient population with limited treatment options, thereby providing a long-term therapeutic strategy Compl. ¶¶4-5

Key Claims at a Glance

  • The complaint asserts infringement of at least claim 1 Compl. ¶80
  • The essential elements of independent claim 1 are:
    • A method for inducing clinical remission in a patient with moderately to severely active ulcerative colitis.
    • The patient is characterized as having had a lack of an adequate response with, lost response to, or was intolerant to a TNFα antagonist.
    • The method comprises intravenously administering a 300 mg dose of an α4β7-specific antibody at week 0, week 2, and week 6, followed by 300 mg doses every eight weeks thereafter.
    • The antibody is defined by specific heavy and light chain variable region sequences (SEQ ID NO:2 and SEQ ID NO:4, respectively).

U.S. Patent No. 12,053,526 - "Methods for Treatment Using anti-alpha4beta7 Antibody"

  • Patent Identification: U.S. Patent No. 12,053,526, titled "Methods for Treatment Using anti-alpha4beta7 Antibody", issued August 6, 2024 Compl. ¶49
  • Technology Synopsis: The patent claims a method for treating UC with a specific vedolizumab dosing regimen (doses at weeks 0, 2, 6, then every 4 or 8 weeks). A key aspect of the invention is that this regimen is asserted to induce not only clinical response and remission but also "tolerance" to the drug, defined as the patient having a human anti-human antibody (HAHA) titer of <125 Compl. ¶102
  • Asserted Claims: Representative claim 7 is asserted Compl. ¶102
  • Accused Features: Polpharma's proposed aBLA product and its dosing regimen are alleged to induce clinical remission and tolerance, thereby infringing the '526 patent Compl. ¶¶109-110

U.S. Patent No. 12,171,832 - "Methods of Treating Ulcerative Colitis"

  • Patent Identification: U.S. Patent No. 12,171,832, titled "Methods of Treating Ulcerative Colitis", issued December 24, 2024 Compl. ¶50
  • Technology Synopsis: The patent covers a method for treating UC in a specific patient sub-population: those who previously had an inadequate response or intolerance to the immunomodulators azathioprine or 6-mercaptopurine. The method uses a specific vedolizumab dosing schedule (weeks 0, 2, 6, then every 8 weeks) to achieve clinical response at 6 weeks and clinical remission at 52 weeks Compl. ¶128
  • Asserted Claims: Representative claim 1 is asserted Compl. ¶128
  • Accused Features: The complaint alleges Polpharma's aBLA product will be recommended for this specific patient population and will achieve the claimed clinical outcomes when administered according to the proposed label Compl. ¶¶131 Compl. ¶133

U.S. Patent No. 12,544,445 - "Methods for Treatment Using anti-a4β7 Antibody"

  • Patent Identification: U.S. Patent No. 12,544,445, titled "Methods for Treatment Using anti-a4β7 Antibody", issued February 10, 2026 Compl. ¶51
  • Technology Synopsis: This patent claims a method of treating inflammatory bowel disease (IBD) with a specific vedolizumab dosing regimen (induction and maintenance phases). A key limitation is that the method produces a "mean trough serum concentration of 20 µg/ml to 30 µg/ml" at the end of the induction phase, which is alleged to be a feature that induces clinical response and remission Compl. ¶153
  • Asserted Claims: Representative claim 1 is asserted Compl. ¶153
  • Accused Features: The administration of Polpharma's aBLA product is alleged to produce the same mean trough serum concentration recited in the claim Compl. ¶157

U.S. Patent No. 12,622,969 - "Methods for Treatment Using anti-a4β7 Antibody"

  • Patent Identification: U.S. Patent No. 12,622,969, titled "Methods for Treatment Using anti-a4β7 Antibody", issued May 12, 2026 Compl. ¶52
  • Technology Synopsis: The patent is directed to a method for treating IBD and minimizing the formation of human anti-human antibodies (HAHA). The claimed method involves a specific vedolizumab dosing regimen that allegedly results in "at least 80% of the human patients" being maintained as HAHA-negative for at least 6 weeks after the initial dose Compl. ¶178
  • Asserted Claims: Representative claim 1 is asserted Compl. ¶178
  • Accused Features: The complaint alleges that administering Polpharma's aBLA product according to its recommended dosing will result in at least 80% of patients being maintained as HAHA-negative, thereby infringing the claim Compl. ¶183

III. The Accused Instrumentality

Product Identification

  • Polpharma Biologics S.A.'s proposed biosimilar vedolizumab product, designated PB016 ("aBLA Product"), for which it has submitted abbreviated Biologics License Application (aBLA) No. 761558 to the FDA Compl. ¶¶7 Compl. ¶35

Functionality and Market Context

  • The aBLA Product is a proposed biosimilar to Takeda's ENTYVIO®, a biologic medicine for treating inflammatory bowel disease (IBD) Compl. ¶¶1 Compl. ¶7 The complaint alleges the product is "designed to be highly similar in its physical and biological characteristics to ENTYVIO®" so that it can be substituted in the market Compl. ¶8 Polpharma is alleged to have conducted Phase III clinical trials comparing the efficacy, safety, and immunogenicity of its product to ENTYVIO® Compl. ¶33 Polpharma has partnered with Fresenius Kabi to commercialize the product in the U.S. and is alleged to be targeting a market with over $5.3 billion in annual sales Compl. ¶¶7 Compl. ¶34

IV. Analysis of Infringement Allegations

The complaint includes a table from the ENTYVIO® label outlining the recommended intravenous dosage, including induction doses at weeks 0 and 2, and maintenance dosing options starting at week 6 Compl. p. 9 This dosing schedule is central to the infringement allegations for the asserted method-of-use patents.

'979 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for achieving clinical response of Crohn's disease in a human patient, wherein said human patient had a lack of an adequate response with, lost response to, or was intolerant to a TNFα antagonist: Polpharma's aBLA Product will be labeled for use in treating moderately to severely active Crohn's disease, and its label and promotional materials will allegedly encourage its use in patients who have failed or are intolerant to TNFα antagonists. Polpharma's Phase III trial specifically targeted this patient population. ¶60 '808 Patent, col. 57:9-12
a first dose of 300 mg of an antibody that has binding specificity for human a4β7 integrin, a second dose of 300 mg of the antibody two weeks after the first dose, and a third dose of 300 mg of the antibody six weeks after the first dose, The proposed label for Polpharma's aBLA Product will instruct administration of 300 mg of vedolizumab at weeks 0, 2, and 6, which directly maps to the claimed induction regimen. ¶57 '808 Patent, col. 78:20-25
wherein the antibody comprises the heavy chain variable region sequence of amino acids 20 to 140 of SEQ ID NO:2, and the light chain variable region sequence of amino acids 20 to 131 of SEQ ID NO:4. The active ingredient in Polpharma's aBLA Product is alleged to be vedolizumab, which comprises the claimed heavy and light chain variable region sequences. ¶59 '808 Patent, col. 78:41-45

'808 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for inducing clinical remission in a human patient having moderately to severely active ulcerative colitis...wherein said human patient had a lack of an adequate response with, lost response to, or was intolerant to a TNFa antagonist. Polpharma's aBLA Product will be labeled for treating moderately to severely active UC, and the complaint alleges Polpharma will promote its use in patients who have failed prior TNFα antagonist therapy. ¶84 '808 Patent, col. 18:19-27
comprising intravenously administering: a first dose of 300 mg ... a second dose ... two weeks after the first dose, a third dose ... six weeks after the first dose, and then 300 mg of the antibody every eight weeks thereafter, The proposed label for Polpharma's aBLA Product is alleged to instruct the exact induction and maintenance dosing regimen recited in the claim. ¶81 '808 Patent, col. 78:20-25
wherein the antibody comprises the heavy chain variable region sequence of amino acids 20 to 140 of SEQ ID NO:2, and the light chain variable region sequence of amino acids 20 to 131 of SEQ ID NO:4... The active ingredient in the aBLA Product is alleged to be vedolizumab, which comprises the specific heavy and light chain variable region sequences defined in the claim. ¶83 '808 Patent, col. 78:41-45

Identified Points of Contention

  • Scope Questions: The core of the dispute appears to be a straightforward application of method-of-use claims to a biosimilar product intended to be used in the same way as the reference product. A primary question for the court will be whether the act of seeking FDA approval for a product with a label that instructs an infringing method constitutes infringement under 35 U.S.C. § 271(e)(2), even before any commercial sales. The complaint's allegations regarding Polpharma's Phase III trial design (Compl. ¶¶33; Compl. ¶60; Compl. ¶84) may be used to suggest Polpharma's specific intent for the product to be used in an infringing manner.
  • Technical Questions: A foundational evidentiary question will be whether Polpharma's aBLA submission and clinical data actually demonstrate that its product, PB016, when administered as instructed, achieves the specific clinical outcomes required by the claims, such as "achieving clinical response" in CD ('579 patent) and "inducing clinical remission" in UC ('808 patent). While the complaint alleges Polpharma's trials assessed these outcomes (Compl. ¶¶60; Compl. ¶84), the strength of that evidence will be a central issue.

V. Key Claim Terms for Construction

The Term: "achieving clinical response" ('579 Patent, claim 1)

  • Context and Importance: This term defines the therapeutic outcome of the claimed method for Crohn's disease. The infringement analysis will depend on whether the use of Polpharma's aBLA product according to its label can be proven to "achieve" this result in the specified patient population.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The related '808 patent defines "clinical response" in the context of Crohn's disease by reference to a standard, objective metric: "a 70 point or greater decrease in CDAI score from baseline" ('808 Patent, col. 14:20-24). Plaintiff may argue this established definition should apply.
    • Evidence for a Narrower Interpretation: A defendant could argue that "achieving" clinical response implies a higher standard than merely observing it in a clinical trial. The '808 patent's detailed examples of clinical trial results (e.g., '808 Patent, col. 57:5-67) may be used to argue that the term is implicitly tied to the specific statistical significance and patient population details described in the specification, potentially creating a narrower definition than a generic reduction in a clinical score.

The Term: "inducing clinical remission" '808 Patent, claim 1

  • Context and Importance: This is the therapeutic endpoint of the claimed method for ulcerative colitis. Its construction is critical because infringement requires showing that Polpharma's product, used as directed, will "induce" this state. Practitioners may focus on this term because the act of "inducing" a state, versus merely being associated with it, can be a point of contention.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The '808 patent provides an explicit and objective definition: "a complete Mayo score of 2 or less points and no individual subscore greater than 1 point" ('808 Patent, col. 14:8-11). Plaintiff will likely argue that this plain language from the specification should control.
    • Evidence for a Narrower Interpretation: The patent specification links the claimed method to specific clinical trial outcomes where remission was achieved ('808 Patent, col. 59:5-60:4). A defendant may argue that "inducing" remission requires meeting a similar level of statistical evidence and efficacy as demonstrated in the patent's own examples, which could set a higher bar than simply showing that some patients achieve the Mayo score endpoint.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that Polpharma will induce infringement by "encourag[ing], promot[ing], and recommend[ing]" that healthcare providers and patients use the aBLA Product in an infringing manner, primarily by providing a product label and prescribing information that instructs the performance of the claimed methods (Compl. ¶55; Compl. ¶63; Compl. ¶79; Compl. ¶87).
  • Willful Infringement: The complaint alleges that Polpharma is "aware, knows, and/or is willfully blind" to the fact that its actions will infringe Takeda's patents (Compl. ¶62; Compl. ¶86). The basis for willfulness is alleged pre-suit knowledge of the patents, as well as knowledge gained from the filing of the complaint itself (Compl. ¶64; Compl. ¶88).

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of causation and clinical proof: Does the evidence submitted in Polpharma's aBLA, including its Phase III clinical trial data, definitively establish that its biosimilar product, when used according to its proposed label, necessarily "achieves clinical response" and "induces clinical remission" as required by the method claims, or is there an evidentiary gap between the trial results and the specific outcomes mandated by the patent language?
  • A second key question will be one of infringement by labeling: In a BPCIA context where the accused product is designed to be a biosimilar, to what extent does a proposed label that mirrors the reference product's approved (and patented) method of use create a per se case of induced infringement, and what defenses, beyond invalidity, can be raised against such an allegation?
  • A third question will focus on patent validity in a crowded field: Will the patents' validity hold up against challenges that the claimed dosing regimens for vedolizumab, even when limited to specific TNFα-failure patient populations, were obvious evolutions of known biologic treatment strategies for inflammatory bowel disease at the time of the invention?